More standardized research is needed to guide second-line agent selection in IgG4-RD. Rituximab offers a highly effective steroid-sparing option for the treatment of immunoglobulin G4-related disease ...

A kidney biopsy showed storiform interstitial fibrosis with IgG4-positive plasma cells, confirming the diagnosis of IgG4-RD. Immunoglobulin G4-related disease (IgG4-RD) is complex and frequently ...

IgG4-RD is a systemic, immune-mediated inflammatory disorder ... The results showed that traditional histopathological markers, like storiform fibrosis and obliterative phlebitis, were present in 71.4 ...

IgG4-RD can lead to fibrosis and permanent organ damage, and it can affect any organ system over time. The heterogeneous and unpredictable inflammatory flares that patients experience mimic the ...

The drug has become the first to receive FDA approval specifically for treating immunoglobulin G4-related disease (IgG4-RD). LAS VEGAS, April 14, 2025 /PRNewswire/ -- IgG4-related disease (IgG4-RD ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen ...

IgG4-RD is a rare, chronic inflammatory condition that can lead to fibrosis and organ damage. The approval is based on the results of the MITIGATE trial, which showed an 87% reduction in the risk ...

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the ...

AIP has two forms of involvement: Type 1 AIP, linked to immunoglobulin G4–related disease (IgG4-RD), and type 2 AIP ... extensive fibrosis, and IgG4-positive plasma cells.

IgG4-RD is a rare, chronic inflammatory condition that can lead to fibrosis and organ damage. The approval is based on the results of the MITIGATE trial, which showed an 87% reduction in the risk of ...